Zhonghong Pulin Medical Products Co. Ltd. (300981) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Zhonghong Pulin Medical Products Co. Ltd. ¥5.24, price ¥20.30, upside -74.2%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range ¥7.57 – ¥41.50 · fair‑value band ¥3.85 – ¥6.62 · the ¥20.30 price screens above the ¥5.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 2, 2026.
Follow Zhonghong Pulin Medical Products Co. in your weekly email
Every Wednesday you see whether Zhonghong Pulin Medical Products Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zhonghong Pulin Medical Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of disposable health products for medical and industrial use in China and internationally. It operates in three segments: Health Protection Division; Safety Infusion Division; and Innovation Incubation Division.
Show more
Zhonghong Pulin Medical Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of disposable health products for medical and industrial use in China and internationally. It operates in three segments: Health Protection Division; Safety Infusion Division; and Innovation Incubation Division. The Health Protection Division offers nitrile gloves, PVC gloves, natural latex gloves, radiation-proof gloves, polyisoprene gloves, examination findom, and condoms, as well as various other disposable exam, surgical, and protective gloves. Its Safety Infusion Division provides infusion equipment-related products, such as precision infusion sets, indwelling needles, common infusion sets, common syringes, and blood collection tubes, etc. The Innovation Incubation Division offers infusion and syringe pumps, infusion information collection systems, disposable non-invasive EEG electrodes, disposable medical temperature sensors, non-invasive blood pressure cuffs, and radial artery compression tourniquets, as well as closed loop temperature management systems, and disposable atomizers. It also provides wireless continuous monitoring sensors and probes; and engages in scientific research and technical services. The company exports its products to approximately 80 countries and regions. Zhonghong Pulin Medical Products Co., Ltd. was founded in 2010 and is based in Tangshan, China.
Stock analysis
Zhonghong Pulin Medical Products Co. Ltd. (300981) currently trades at ¥20.30, while our model-based Fair Value estimate is ¥5.24, 74.2% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 2 models at a data quality of 91/100, which puts the evidence level at low.
Scenario range: ¥3.85 (bear) to ¥6.62 (bull), the price of ¥20.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Zhonghong Pulin Medical Products Co. Ltd. reported revenue of 2.4B CNY in FY2025 versus 4.9B CNY in FY2021, a compound −16.6%/yr. Reported net income was −112M CNY in FY2025.
Key figures
Market cap 8.7B CNY (≈ $1.3B) · P/E ratio 203.0 · P/S ratio 3.33 · EPS (TTM) ¥0.1000 · Dividend yield 1.7% · Net margin −4.7% · Return on equity 0.7% · Return on assets (EBIT) 7.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 114% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −37% fair-value upside, at −74%, 300981 screens richer than that median.
Fair Value models
Bear ¥3.85Fair Value ¥5.24Bull ¥6.62
Price ¥20.30 · Upside -74.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.14/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−3.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−13.1%
Start year 2020 (pandemic). Over 10 years: +14.7% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
66.8% (2020) → −2.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Zhonghong Pulin Medical Products Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 191 stocks
Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score47 · Below median
Fair Value upside−74.2% · Bottom 25%
Profitability
Return on equity (TTM)0.7% · Below median
Return on assets0.9% · Bottom 25%
Net margin (TTM)1.6% · Below median
Operating margin (TTM)20.1% · Top 25%
Growth and dividend
Revenue growth44.1% · Top 25%
Dividend yield (TTM)1.7% · Above median
Balance sheet
Debt / equity0.04× · Below median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (TTM)203.0× · Priciest 25%
P/B1.65× · Cheaper than median
P/S (TTM)3.33× · Pricier than median
EV/EBITDA24.5× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 15
FUTURE (revenue growth)100· sector 36
PAST (return on equity)3· sector 28
HEALTH (low debt)98· sector 96
DIVIDEND (yield)34· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zhonghong Pulin Medical Products Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/300981
Frequently asked questions
Is Zhonghong Pulin Medical Products Co. Ltd. (300981) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ¥5.24 versus the last price from Sep 30, 2026 of ¥20.30, about −74% upside (overvalued).
What is the fair value of 300981?
Our model-based fair value for Zhonghong Pulin Medical Products Co. Ltd. is ¥5.24 (as of Oct 2, 2026), built from audited fundamentals. Last price (from Sep 30, 2026): ¥20.30.
What is the quality score of 300981?
Zhonghong Pulin Medical Products Co. Ltd. has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhonghong Pulin Medical Products Co. Ltd. (300981)?
Our model-based price target is the fair value of ¥5.24 (as of Oct 2, 2026) from 2 valuation models. Cautious scenario ¥3.85, optimistic scenario ¥6.62. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhonghong Pulin Medical Products Co. Ltd. stock forecast for 2026?
Our models put fair value at ¥5.24, about −74% upside versus the last price from Sep 30, 2026 of ¥20.30 (overvalued). Cautious scenario ¥3.85, optimistic scenario ¥6.62. The calculation is refreshed regularly with new filings.
What is the revenue of Zhonghong Pulin Medical Products Co. Ltd. (300981)?
Zhonghong Pulin Medical Products Co. Ltd. reported trailing-twelve-month revenue of about 2.6B CNY (latest available figure, as of Oct 2, 2026).
Does Zhonghong Pulin Medical Products Co. Ltd. pay a dividend?
Zhonghong Pulin Medical Products Co. Ltd. currently shows a dividend yield of about 1.72% relative to its recent price (as of Oct 2, 2026).
What is the intrinsic value of Zhonghong Pulin Medical Products Co. Ltd. (300981)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhonghong Pulin Medical Products Co. Ltd. it is ¥5.24 per share (as of Oct 2, 2026), against a price of ¥20.30. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Zhonghong Pulin Medical Products Co. Ltd. stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 300981 trades above its calculated fair value: price ¥20.30, fair value ¥5.24, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300981?
No. The price is what the market pays today (¥20.30); the fair value is what the company's own numbers justify (¥5.24). For Zhonghong Pulin Medical Products Co. Ltd. the two are ¥15.06 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhonghong Pulin Medical Products Co. Ltd. worth?
The market values Zhonghong Pulin Medical Products Co. Ltd. at about 8.7B CNY (market capitalisation, as of Oct 2, 2026). Per share that is ¥20.30; our models calculate a fair value of ¥5.24 per share.
What do the bullish and bearish scenarios say about 300981?
Our models span a range for Zhonghong Pulin Medical Products Co. Ltd.: cautious scenario ¥3.85, base ¥5.24, optimistic ¥6.62 per share (as of Oct 2, 2026, price ¥20.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300981?
Zhonghong Pulin Medical Products Co. Ltd. trades at a price-to-earnings ratio of 203.0 (as of Oct 2, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥5.24 is built from several models across several years. Other multiples: P/B 1.7, P/S 3.3, EV/EBITDA 24.5.
How solid is the balance sheet of Zhonghong Pulin Medical Products Co. Ltd. (300981)?
Balance-sheet figures for Zhonghong Pulin Medical Products Co. Ltd. (as of Oct 2, 2026): return on equity 0.7%, debt of 0.04 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 300981 from its 52-week high?
Zhonghong Pulin Medical Products Co. Ltd. trades at ¥20.30, at its 52-week high of ¥20.30 and 114% above the low of ¥9.50 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥5.24 is for.
Which stocks are comparable to Zhonghong Pulin Medical Products Co. Ltd.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhonghong Pulin Medical Products Co. Ltd. stock attractive at the current price?
The data as of Oct 2, 2026: price ¥20.30, calculated fair value ¥5.24 (−74%), Quality Score 47/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300981 calculated?
We run Zhonghong Pulin Medical Products Co. Ltd. through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥5.24, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.4 % above its aggregate fair value. Zhonghong Pulin Medical Products Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhonghong Pulin Medical Products Co. Ltd. (300981)?
The latest price we hold is from Sep 30, 2026 and stands at ¥20.30. Our model-based fair value is ¥5.24, about −74% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhonghong Pulin Medical Products Co. Ltd. right now?
The price sits above even our optimistic bull case (¥6.62). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Zhonghong Pulin Medical Products Co. Ltd.
How large is the market capitalisation of Zhonghong Pulin Medical Products Co. Ltd. (300981)?
The market capitalisation of Zhonghong Pulin Medical Products Co. Ltd. is 8.7B CNY (≈ $1.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhonghong Pulin Medical Products Co. Ltd. (300981)?
The price-to-sales ratio of Zhonghong Pulin Medical Products Co. Ltd. is 3.33 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhonghong Pulin Medical Products Co. Ltd. (300981)?
Earnings per share at Zhonghong Pulin Medical Products Co. Ltd. are ¥0.1000 (price ÷ EPS = P/E 203.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhonghong Pulin Medical Products Co. Ltd. (300981)?
The dividend yield of Zhonghong Pulin Medical Products Co. Ltd. is 1.7%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhonghong Pulin Medical Products Co. Ltd. (300981)?
The net margin of Zhonghong Pulin Medical Products Co. Ltd. is −4.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhonghong Pulin Medical Products Co. Ltd. (300981)?
The return on equity (ROE) of Zhonghong Pulin Medical Products Co. Ltd. is 0.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhonghong Pulin Medical Products Co. Ltd. (300981)?
On an EBIT basis the return on assets of Zhonghong Pulin Medical Products Co. Ltd. is 7.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhonghong Pulin Medical Products Co. Ltd. (300981)?
The operating margin of Zhonghong Pulin Medical Products Co. Ltd. is 20.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhonghong Pulin Medical Products Co. Ltd. (300981)?
Revenue at Zhonghong Pulin Medical Products Co. Ltd. is growing +44.1% versus a year earlier (3y avg +14.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhonghong Pulin Medical Products Co. Ltd. (300981)?
Earnings per share at Zhonghong Pulin Medical Products Co. Ltd. are growing −74.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zhonghong Pulin Medical Products Co. Ltd. (300981) generate?
The free cash flow of Zhonghong Pulin Medical Products Co. Ltd. is −187M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zhonghong Pulin Medical Products Co. Ltd. (300981) carry?
The net debt of Zhonghong Pulin Medical Products Co. Ltd. is 133M CNY (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Zhonghong Pulin Medical Products Co. Ltd. in the live analysis
One click puts Zhonghong Pulin Medical Products Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
